Chengdu Shuode Pharmaceutical Co.,Ltd.

Main research purpose: According to the relevant provisions of bioequivalence test, Hainan Xiansheng Pharmaceutical Co., Ltd. was selected as the reference preparation of Aguratimod Tablets (trade name: Edexin, specification: 25mg), and the test preparation Aguratimod Tablets (specification: 25mg) produced and provided by Chengdu Shuode Pharmaceutical Co., Ltd. was conducted on the human bioequivalence test of fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation Aguratimod Tablets (specification: 25mg) and the reference preparation Aguratimod Tablets (trade name: Edexin, specification: 25mg) by healthy volunteers.

Main study purpose: According to the relevant provisions of bioequivalence test, the certified Eperisone Hydrochloride Tablets (trade name: Miaona, specification: 50mg) of Eisai (China) Pharmaceutical Co., Ltd. were selected as the reference preparation, and the test preparation Eperisone Hydrochloride Tablets (specification: 50mg) produced and provided by Chengdu Shuode Pharmaceutical Co., Ltd. were subjected to human bioequivalence test on fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation Eperisone Hydrochloride Tablets (specification: 50mg) and the reference preparation Eperisone Hydrochloride Tablets (trade name: Miaona, specification: 50mg) to healthy subjects.

Main study purpose: According to the relevant provisions of bioequivalence test, the perindopril amlodipine tablets (III) (trade name: Kaisuda®, specification: 10mg/5mg) of Les Laboratoires Servier as the licensee was selected as the reference preparation, and the human bioequivalence test of the test preparation perindopril amlodipine tablets (III) (specification: 10mg/5mg) produced by Chengdu Shuode Pharmaceutical Co., Ltd. was conducted on the fasting administration of the test preparation perindopril amlodipine tablets (III) (specification: 10mg/5mg) to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation perindopril amlodipine tablets (III) (specification: 10mg/5mg) and the reference preparation perindopril amlodipine tablets (III) (trade name: Kaisuda®, specification: 10mg/5mg) by healthy volunteers.